Loading…

Bioventus will acquire Misonix in a cash-and-stock transaction valued at approximately $518 million, adding minimally invasive ultrasonic technologies and regenerative medicine products.
“The Combination Further Differentiates Bioventus’ Product Portfolio and Accelerates Its Revenue Growth”ir.bioventus.com
Summarized from public sources; check the original articles before acting on it.